Journal Article

Antimicrobial Resistance among and Therapeutic Options against Gram-Negative Pathogens

James J. Rahal

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 49, issue Supplement_1, pages S4-S10
Published in print August 2009 | ISSN: 1058-4838
Published online August 2009 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/599810
Antimicrobial Resistance among and Therapeutic Options against Gram-Negative Pathogens

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Gram-negative bacterial pathogens are a common cause of infection, and the prevalence and rates of resistance among these pathogens to existing antimicrobial agents are increasing. β-Lactamase-mediated resistance is of particular concern. High-level resistance attributable to β-lactamase expression alone or in combination with other mechanisms is becoming increasingly prevalent among Enterobacteriaceae and gram-negative nonfermenting organisms. Doripenem is a new carbapenem with strong coverage of difficult-to-treat gram-negative bacterial pathogens. Its activity against Pseudomonas aeruginosa exceeds that of other carbapenems, and it has equivalent activity against Acinetobacter species and most Enterobacteriaceae. Thus, doripenem may be valuable alone or in combination with other agents in the treatment of serious gram-negative infections.

Journal Article.  4267 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.